GeNeu­ro touts a mixed set of ex­ten­sion da­ta in a shot at sal­vaging their failed mid-stage MS drug

Gene­va-based GeNeu­ro man­aged to earn a spike in its share price af­ter tout­ing a dis­tinct­ly mixed set of Phase IIb ex­ten­sion da­ta for their failed mul­ti­ple scle­ro­sis drug teme­limab.

Bull­ish­ly en­cour­ag­ing in their look at whether the drug could in­flu­ence dis­ease pro­gres­sion, the tri­al failed to hit sta­tis­ti­cal sig­nif­i­cance for sev­er­al key end­points, in­clud­ing a low­er prob­a­bil­i­ty for a con­firmed 12-week wors­en­ing in dis­abil­i­ty rel­a­tive to the con­trol group, where the p-val­ue for the high dose hit 0.34. The p-val­ue for the re­duc­tion of brain at­ro­phy in the cor­tex — a bio­mark­er for the dis­ease — al­so fell short, at 0.058, with at­ro­phy in the thal­a­mus cross­ing the line at a pos­i­tive 0.038.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.